This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Chelsea Therapeutics' CEO Discusses Completion Of EoR Meeting With FDA For Northera Capsules NDA (Transcript)

Chelsea Therapeutics International, Ltd. (CHTP)

Completion of EoR Meeting with FDA for Northera Capsules NDA

May 23, 2012 8:30 AM ET


Kathryn McNeil – Head-Investor & Media Relations

Simon Pedder – President & CEO

Nick Riehle – VP-Administration and CFO

Bill Schwieterman – Chief Medical Officer

Art Hewitt – Chief Scientific Officer


Robyn Karnauskas – Deutsche Bank Securities, Inc.

Alan Carr – Needham & Company

Liana Moussatos – Wedbush Securities, Inc.

Juan Sanchez – Ladenburg Thalmann Securities.

Steven Salamon – ROSALIND Advisors



Good day ladies and gentlemen, and welcome to the Chelsea Therapeutics May 22 Conference Call. At this time, all participants are in a listen-only mode. Later, we’ll conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions)

As a reminder this conference is being recorded.

I would now like to turn the call over to your host, Kathryn McNeil. Please go ahead.

Kathryn McNeil

Thank you operator. Good morning everyone and thank you for joining us for our call this morning. A press release related to today’s call can be found on our website,

Joining me from Chelsea this morning is Simon Pedder, our President, Chief Executive Officer, Mr. Nick Riehle, our Chief Financial Officer, Dr. Bill Schwieterman, Chief Medical Officer and Dr. Art Hewitt, Chief Scientific Officer.

Following formal remarks by Dr. Pedder, the conference call will open for questions. However, before I turn the call over to Dr. Pedder to get us going, let me note that some of the remarks you’ll hear today contain forward-looking statements regarding future events including our intention to modify the primary endpoint for Study 306B, submit additional data to the FDA, resubmit the NDA for the treatment of Neurogenic OH, anticipated expenses for 2012, cash levels and liquidity to fund the company’s operating plans and the company’s anticipated performance.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs